Routine annual meeting filing with no immediate stock-moving implications. The increase in authorized shares for equity grants is standard and already anticipated. Monitor for any future insider selling or large grant activity under the amended plan.
Price Chart
Executive Summary
Agios Pharmaceuticals held its 2026 Annual Meeting on June 18, 2026. Stockholders re-elected three Class I directors, approved an advisory vote on executive compensation, ratified PricewaterhouseCoopers as independent auditor, and approved an amendment to the 2023 Stock Incentive Plan increasing authorized shares by 2,000,000. The filing is routine with no material financial impact.
Key Facts
- Stockholders approved an amendment to the 2023 Stock Incentive Plan, increasing authorized shares by 2,000,000.
- Directors Rahul Ballal, Brian Goff, and Cynthia Smith were re-elected to three-year terms.
- Advisory vote on executive compensation passed with 43,396,045 votes for and 1,086,059 against.
- Ratification of PricewaterhouseCoopers LLP as independent auditor was approved with 48,511,213 votes for.
- Cynthia Smith received 14,592,704 withheld votes (31.7% of votes cast), indicating notable shareholder dissent.
Financial Impact
2,000,000 additional shares authorized for issuance under the stock incentive plan, representing approximately 3.6% dilution based on current outstanding shares (approx. 55.5M shares outstanding per market data).
Risk Factors
- Potential dilution from future equity awards under the amended plan, though capped at 2M shares.
- Cynthia Smith's elevated withheld votes may signal governance concerns to monitor.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-275879 |
| Document: 0001193125-26-275879-index-headers.html | 0001193125-26-275879 |
| Document: 0001193125-26-275879-index.html | 0001193125-26-275879 |
| Document: 0001193125-26-275879.txt | 0001193125-26-275879 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 144 | $36.85 | awaiting T+60 | — | $36.85 (−0.00%) |
Oct 22, 2026 4d ago | 144 | $37.00 | awaiting T+60 | — | $36.85 (−0.41%) |
Aug 6, 2026 11w ago | Institutional Cluster | $31.95 | awaiting T+60 | — | $36.85 (+15.34%) |
Jul 30, 2026 12w ago | 8-K | $32.75 $37.00 | ▲ +12.98% | ▲ +10.51% | $36.85 (+12.52%) |
Jul 30, 2026 12w ago | Press Release | $32.75 $37.00 | ▲ +12.98% | ▲ +10.51% | $36.85 (+12.52%) |
Jul 7, 2026 15w ago | Press Release | $44.01 $33.25 | ▼ −24.45% | ▼ −26.44% | $36.85 (−16.27%) |
Jun 29, 2026 17w ago | Press Release | $38.04 $34.97 | ▼ −8.07% | ▼ −12.46% | $36.85 (−3.13%) |
Jun 18, 2026 18w ago | 8-K | $35.10 $32.81 | ▼ −6.52% | ▼ −8.27% | $36.85 (+4.99%) |
Jun 13, 2026 19w ago | Press Release | $31.82 $34.63 | ▲ +8.83% | ▲ +7.83% | $36.85 (+15.81%) |
Jun 1, 2026 21w ago | Press Release | $28.00 $33.90 | ▲ +21.07% | ▲ +19.84% | $36.85 (+31.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers